Search This Blog

Monday, August 10, 2026

Tenax Therapeutics' Phase 3 LEVEL trial of TNX-103 in PH-HFpEF fails primary, key secondary endpoints


  • Company will seek a Type C FDA meeting to revise TNX-103 registrational development plan after trial failure.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)